These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32294103)

  • 1. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
    Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
    PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
    Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
    Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
    Torabi A; Amaya CN; Wians FH; Bryan BA
    Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
    Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
    Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature.
    Cunningham CR; Dodd L; Esebua M; Layfield LJ
    Ann Diagn Pathol; 2021 Dec; 55():151823. PubMed ID: 34656856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
    Kelany M; Barth TF; Salem D; Shakweer MM
    Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
    [No Abstract]   [Full Text] [Related]  

  • 8. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of programmed death-ligand 1 expression in sarcomas.
    Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
    J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
    Paydas S; Bagir EK; Deveci MA; Gonlusen G
    Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
    Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
    Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
    Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
    Perisano C; Vitiello R; Sgambato A; Greco T; Cianni L; Ragonesi G; Malara T; Maccauro G; Martini M
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 3):289-294. Congress of the Italian Orthopaedic Research Society. PubMed ID: 33261292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy.
    Neyaz A; Husain N; Kumari S; Gupta S; Shukla S; Arshad S; Anand N; Chaturvedi A
    Histopathology; 2018 Oct; 73(4):622-633. PubMed ID: 29882997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.